reason report
bottom line remain outperform agil given lead
posit chemic energi end-market maintain
well-diversifi posit across healthcar growth market
pharma lst diagnost agil saw strong growth pharma
chemic china end-market deliv organ
growth quarter well street expect agil
also remain true margin expans stori deliv bp
yoy oper margin expans pt
pharma growth driven uptak icp-m metal
analysi drug grow requir usp unit state
growth quarter driven believ uptak icp-m
induct coupl plasma mass spec larg due demand
metal analysi drug requir new unit state
pharmacopeia regul agil leader icp-m
market share agil unlik see declin growth
near term believ rest lc-m busi includ
innov ultivo mass spec continu deliv well
chemic deliv strong growth chemic
market account agil revenu deliv
organ growth quarter though agil quantifi uptak
latest gc-m intuvo believ uptak broad-bas
market pent-up demand though hard imagin anoth
quarter growth believ end-market back track
continu see robust growth recal agil uniqu
asset space differenti chemical/energi exposur
well-entrench healthcar
nasd busi lumpi believ remain sourc signific
manufactur oligo therapeut compani includ alnylam
recent approv onpattro given two major
manufactur therapeut oligo inclin think
agil see almost revenu oligo therapeut
product today complet build
facil colorado
china tariff still like weigh agil despit quantifi
overal impact last quarter agil saw flat sale
china due reorgan multipl food agenc ministri
nmsa nation market supervis administr chines
govern agil china sale rebound growth
primarili pharma chemic growth
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu us million ep exclud item amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
offset temporari slow instrument sale food
environment market major problem last quarter investor
tariff manag note china
 revenu hit manag
expect reduc go way
china tariff current expect impact though
fundament believ agil remain strong china
revenu investor believ like watch tariff close
didier hirsch miss mani known
year tenur agil welcom robert
mcmahon cfo didier hirsh retir soon leav rein cfo
robert mcmahon join agil mp bring wealth
experi hirsch work mcmahon transit
cfo role c-suit agil sad see didier
hirsch departur acknowledg well-balanc cfo
understood nuanc intricaci research tool industri
great contributor agil success year
said believ mcmahon experienc well-posit
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium long-term spin-off keysight
electron manag busi becom pure-play life scienc tool lst
compani agil focus deliv adjust oper margin
believ achiev exceed longer term leadership ceo mcmullen
agil compet aggress multipl market deliv solid growth biopharma
sale maintain either posit across end-market
includ food environment chemical/energi emerg market includ china
continu post double-digit growth agil posit capit given sizabl exposur
geographi intuvo product cycl could repres opportun
current under-appreci agil repres compani develop core root
industri chemic electron market year transform life
scienc tool technolog leader diversifi access lead end-market
agil share current trade ev/ebitda under-valued compar
life scienc tool peer group averag
believ ev/ebitda valuat provid best measur agil valu
price target increas expect agil trade premium
averag lst group ev/ebitda multipl result appli
ev/ebitda multipl ebitda estim given number tailwind
posit agil better compar lst peer group continu exposur robust
biopharma growth china demand believ premium warrant sustain
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would
result downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive
use agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead
lower activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar thousand except ep
revenu
life scienc appli market
diagnost genom
life scienc appli market
diagnost genom
estimate
mid-point
china impact
keysight
expect
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report leerink partner estim
